The quest for true randomness has roots in cryptography and is a rabbit hole that gets surprisingly deep with alarmingly rapidity. Still, the generation of random-enough numbers is a popular hacker ...

AI vulnerability scanning is moving into developer workflows. Claude Security turns findings into prioritized fix guidance. The big challenge is keeping these tools from attackers. Anthropic has ...

Companies are scrambling to deal with the glut. Credit...Mojo Wang Supported by By Mike Isaac and Erin Griffith Reporting from San Francisco When a financial services company recently began using ...

Yesterday’s surprise leak of the source code for Anthropic’s Claude Code revealed a lot about the vibe-coding scaffolding the company has built around its proprietary Claude model. But observers ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Pills, tablets and capsules on world map with charts blue background. International ...

With Claude enjoying a moment of newfound popularity among regular people, Anthropic is previewing an update designed to make its chatbot better at explaining some concepts. Starting today, Claude can ...

Generate Biomedicines Inc. raised $400 million in an initial public offering, pricing its shares at the midpoint of the marketed range. The Somerville, Massachusetts-based drug developer sold 25 ...

Feb 26 (Reuters) - Generate Biomedicines said on Thursday that it raised $400 million in its U.S. initial public offering, pricing shares of the U.S.-based drug developer at $16 each. The offering ...

Generate Biomedicines Inc., a biotechnology firm using artificial intelligence in drug development, is seeking to raise as much as $425 millon in an initial public offering, as listing activity in the ...

In recent years, wind energy has been one of the most popular renewable energies for the production of electrical energy, both for isolated sites and as a backup for connected networks. It can be a ...

Generate Biomedicines, Inc. (GENB) has filed to raise public capital in an IPO to advance its pipeline of treatment candidates, according to an SEC filing. The company is developing treatments for ...

Generate:Biomedicines' anti-TSLP antibody GB-0895 is currently being evaluated in a pair of phase 3 studies for severe asthma. (Stock photo/Getty Images) Clinical-stage antibody company ...